Health care stocks were steady premarket Friday as the iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was slightly lower recently.
Alnylam Pharmaceuticals (ALNY) shares rose past 4% after the company said the US Food and Drug Administration has approved the supplemental new drug application for its heart drug Amvuttra.
Telix Pharmaceuticals (TLX) shares advanced nearly 4% after the company said the US Food and Drug Administration has approved its new drug application for Gozellix, a PSMA-PET imaging agent for prostate cancer.
Dyne Therapeutics (DYN) appointed Erick Lucera as chief financial officer, effective March 31. Dyne Therapeutics shares were nearly 7% lower pre-bell.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。